Experts Issue Treatment Guidelines for Aggressive Form of Breast Cancer
Up to one-fifth of patients will have these 'HER2-positive' tumors, oncologists' group says (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - May 5, 2014 Category: Cancer & Oncology Source Type: news

Promising drug doubles positive effect in hormone-receptor–positive breast cancer
Breast cancer researchers from the Revlon/UCLA Women's Cancer Research Program at UCLA's Jonsson Comprehensive Cancer Center announced final clinical trial results this week that showed the amount of time patients were on treatment without their cancer worsening (called "progression-free survival") was effectively doubled in women with advanced breast cancer who took the experimental drug palbociclib.   The results of the phase 2 clinical trial were announced at the American Association for Cancer Research annual meeting in San Diego.   Palbociclib (PD 0332991) is an investigational drug discovered and ...
Source: UCLA Newsroom: Health Sciences - April 11, 2014 Category: Universities & Medical Training Source Type: news

Promising drug doubles positive effect in hormone-receptor–positive breast cancer
Breast cancer researchers from the Revlon/UCLA Women's Cancer Research Program at UCLA's Jonsson Comprehensive Cancer Center announced final clinical trial results this week that showed the amount of time patients were on treatment without their cancer worsening (called "progression-free survival") was effectively doubled in women with advanced breast cancer who took the experimental drug palbociclib.   The results of the phase 2 clinical trial were announced at the American Association for Cancer Research annual meeting in San Diego.   Palbociclib (PD 0332991) is an investigational drug discovered and ...
Source: UCLA Newsroom: Health Sciences - April 11, 2014 Category: Universities & Medical Training Source Type: news

Novel Drug 'Graduates' in Breast Ca Trial (CME/CE)
SAN DIEGO (MedPage Today) -- A targeted therapy for breast cancer "graduated" to phase III eligibility for patients with HER2-positive/hormone receptor-negative disease, data from an ongoing trial showed. (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 11, 2014 Category: American Health Source Type: news

Eisai begins Phase III breast cancer study
US subsidiary of Japan-based Eisai has initiated a large, randomised Phase III trial to compare the efficacy, safety and tolerability of eribulin mesylate injection to standard weekly paclitaxel as a first or second- line treatment for HER2-negative … (Source: Drug Development Technology)
Source: Drug Development Technology - March 3, 2014 Category: Pharmaceuticals Source Type: news

Triple Negative Breast Cancer - Description,...
Triple negative breast cancer cells have no receptors for estrogen, progesterone, or HER2 protein. This type of breast cancer tends to be aggressive and survival rates are lower than average. Learn who is more at risk, and how triple negative breast cancer (TNBC) is treated. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - February 28, 2014 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Oncothyreon and Array begin Phase Ib breast cancer combination therapy study
Oncothyreon and Array BioPharma have started a Phase Ib study of ONT-380 (ARRY-380) in combination with Kadcyla (ado-trastuzumab emtansine or TDM-1) for the treatment of patients with metastatic HER2+ breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - February 24, 2014 Category: Pharmaceuticals Source Type: news

Natural compound attacks HER2 positive breast cancer cells
(Duke University Medical Center) A common compound known to fight lymphoma and skin conditions actually has a second method of action that makes it particularly deadly against certain aggressive breast tumors, researchers at Duke Medicine report. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 17, 2014 Category: Cancer & Oncology Source Type: news

Hot Topics: High Marks for Anti-HER2 Agents
(MedPage Today) -- Asked what works and what doesn't in breast cancer, four leaders in the field linked improved survival to adjuvant therapy and anti-HER2 agents, but all four said metastatic breast cancer remains a frustrating, incurable disease. (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - February 10, 2014 Category: Geriatrics Source Type: news

Oncothyreon and Array start phase 1b ONT-380 combination trial to treat metastatic HER2+ breast cancer
US-based Oncothyreon and Array BioPharma have started a phase 1b trial of ONT-380 (ARRY-380) in combination with Xeloda (capecitabine) and/or Herceptin (trastuzumab) for the treatment of patients with metastatic HER2+ breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - February 4, 2014 Category: Pharmaceuticals Source Type: news

Roche delivers strong 2013 results
Group sales rise 6% to 46.8 billion Swiss francs; Pharmaceuticals sales 7% higher, driven by HER2 breast cancer franchise, Avastin, MabThera/Rituxan, Actemra/RoActemra and Lucentis. Diagnostics sales up 4% on strong Professional Diagnostics performance (Source: Roche Investor Update)
Source: Roche Investor Update - January 30, 2014 Category: Pharmaceuticals Source Type: news

Novel HER2 mutation identified in familial lung adenocarcinomas
Researchers have identified a novel germline mutation in the transmembrane domain of the human epidermal growth factor receptor 2 gene in familial lung adenocarcinomas. (Source: MedWire News - Lung Cancer)
Source: MedWire News - Lung Cancer - January 24, 2014 Category: Cancer & Oncology Source Type: news

Novel HER2 mutation identified in familial lung adenocarcinomas
Researchers have identified a novel germline mutation in the transmembrane domain of the human epidermal growth factor receptor 2 gene in familial lung adenocarcinomas. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 24, 2014 Category: Cancer & Oncology Source Type: news

Mayo Clinic Scientists Propose a Breast Cancer Drug for Bladder Cancer Patients
http://www.youtube.com/watch?v=iwATErIogm0 ROCHESTER, Minn. ― Jan. 21, 2014 ― Researchers at Mayo Clinic have found amplification of HER2, a known driver of some breast cancers, in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC) and have shown that the presence of HER2 amplification is associated with particularly aggressive tumors. These findings suggest that administering [...] (Source: Mayo Clinic Research News)
Source: Mayo Clinic Research News - January 21, 2014 Category: Research Source Type: news

VHIO genomic study identifies subgroups of HER2+ breast cancer with varying sensitivities
(Vall d´Hebron Institute of Oncology) VHIO describes as many as four subgroups of HER2+ breast cancer (Luminal A, Luminal B, HER2-enriched and Basal-Like) with varying responses and benefits resulting from combined anti-HER2 targeted therapy and chemotherapyThe first diagnostic test for these different breast cancer subtypes will soon be available at VHIO which will be key to ongoing studies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 17, 2014 Category: Cancer & Oncology Source Type: news

Biomarker Data Improve Breast Cancer Staging AccuracyBiomarker Data Improve Breast Cancer Staging Accuracy
Inclusion of estrogen receptor, progesterone receptor, and human epidermal growth factor 2 (HER2) status could improve the prognostic accuracy of breast cancer staging, according to a new study. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 26, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Finally! Data in Low-Risk HER2 Breast CancerFinally! Data in Low-Risk HER2 Breast Cancer
Drs. Kathy Miller and Ian Krop talk about why a single-arm study in low-risk cancer is a huge advance for a population of understudied breast cancer patients. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 24, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Progression of advanced breast cancer not delayed by new combination therapy
Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented at the 2013 San Antonio Breast Cancer Symposium."Patients with metastatic or recurrent breast cancer, as well as those with locally advanced disease that cannot be surgically removed, have no curative options," said John R. Mackey, M.D., professor of oncology at the University of Alberta in Edmonton. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 18, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

New drug combination delayed disease progression for subgroup of women with metastatic breast cancer
Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14.Dasatinib is approved by the U.S. Food and Drug Administration for the treatment of chronic myelogenous leukemia. One of the ways it works is by blocking the activity of a protein called Src, which has been recently implicated in the spread of breast cancer to bones. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 17, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Studies Point to Challenges of HER2 Resistance
SAN ANTONIO (MedPage Today) -- A common mutation in HER2-positive breast cancer reduced the odds of pathologic complete response to neoadjuvant therapy by 50%, an analysis of two large clinical trials showed. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 16, 2013 Category: Hematology Source Type: news

In lower-risk breast cancer patients, Herceptin plus Taxol highly effective
A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol, a study has found.The study is the first major trial to examine the Herceptin-Taxol combination in patients who have a type of breast cancer with the biology known as small, node-negative, HER2+. Results were presented during the 2013 San Antonio Breast Cancer Symposium. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 13, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Highly effective treatment option identified for patients with HER2-positive breast cancer
Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 13, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Identifying breast cancer patients most likely to benefit from trastuzumab
Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 13, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

New combination therapy fails to delay progression of advanced breast cancer
(American Association for Cancer Research) Adding the antibody therapy ramucirumab to the chemotherapy drug docetaxel did not delay disease progression for patients with HER2-negative, advanced breast cancer, according to results of a placebo-controlled, randomized, phase III clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 13, 2013 Category: Cancer & Oncology Source Type: news

Study Predicts Moderate Benefit of Trastuzumab in HER2-Negative Breast C...Study Predicts Moderate Benefit of Trastuzumab in HER2-Negative Breast C...
Although trastuzumab (Herceptin) is directed against the HER2 protein, patients with HER2-negative breast cancer might also benefit from adjuvant trastuzumab therapy, new research suggests. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 12, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Boston Doctor Part Of Study That Could Change Treatment For Some Breast Cancers
BOSTON (CBS) — A new study may change the way some breast cancers are treated. WBZ NewsRadio 1030′s Diane Stern reports play pause Boston Doctor Part Of Study That Could Change Treatment For Some Breast Cancers Diane Stern Dr. Eric Winer, chief of the division of Women’s Cancers in the Susan F. Smith Center for Women’s Cancers at Dana-Farber,says researchers have discovered women with relatively small, H...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - December 12, 2013 Category: Consumer Health News Authors: Kckatzman Tags: Breast Cancer Health Healthwatch Local Seen On WBZ-TV Syndicated Local Uncategorized Watch Listen CBS Boston Dana Farber Cancer Institute Diane Stern Dr Eric Winer Research Source Type: news

New drug combination delayed disease progression for subgroup of women with metastatic breast cancer
(American Association for Cancer Research) Adding the drug dasatinib to a standard antihormone therapy, letrozole, doubled the time before disease progressed for women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results of a phase II clinical trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 12, 2013 Category: Global & Universal Source Type: news

PIK3CA gene mutations make HER2- and hormone receptor-positive breast cancers treatment-resistant
(American Association for Cancer Research) Women with breast cancer characterized by high levels of the protein HER2 and hormone receptors gained much less benefit from presurgery treatment with chemotherapy and HER2-targeted therapies if their cancer had one or more mutations in the PIK3CA gene, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 12, 2013 Category: Global & Universal Source Type: news

New Treatment for Aggressive Breast Cancer Shows Some Promise
Early studies found small improvement with combo therapy for HER2-positive disease (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - December 12, 2013 Category: Cancer & Oncology Source Type: news

Avastin Misses Mark Again in Breast Cancer (CME/CE)
SAN ANTONIO (MedPage Today) -- The addition of bevacizumab (Avastin) to standard adjuvant therapy for HER2-positive breast cancer failed to improve invasive disease-free survival in a randomized clinical trial. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 12, 2013 Category: Hematology Source Type: news

New Treatment for Aggressive Breast Cancer Shows Some Promise
Early studies found small improvement with combo therapy for HER2-positive disease (Source: WebMD Health)
Source: WebMD Health - December 11, 2013 Category: Consumer Health News Source Type: news

New Treatment for Aggressive Breast Cancer Shows Some Promise
Early studies found small improvement with combo therapy for HER2-positive disease (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 11, 2013 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Nursing, Oncology, Pharmacy, News, Source Type: news

Study identifies highly effective treatment option for patients with HER2-positive breast cancer
(American Association for Cancer Research) Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumor size and whether or not disease has spread to the lymph nodes, according to results from the BETH study presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2013 Category: Cancer & Oncology Source Type: news

High levels of immune cells in tumors may ID breast cancer pts most likely benefit from trastuzumab
(American Association for Cancer Research) Women with HER2-positive breast cancer who had the highest levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2013 Category: Cancer & Oncology Source Type: news

Combined therapy linked to lower chance of recurrence in women with small, HER2+ breast cancers
(Dana-Farber Cancer Institute) In a new study, women with relatively small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted therapy following surgery or radiation therapy were very unlikely to have the cancer recur within a few years of treatment, investigators at Dana-Farber Cancer Institute and other research centers will report at the 2013 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 11, 2013 Category: Cancer & Oncology Source Type: news

Timing of Trastuzumab Administration in Breast CancerTiming of Trastuzumab Administration in Breast Cancer
In the neoadjuvant treatment of HER2-positive breast cancer, administering trastuzumab concurrently with anthracyclines offers no advantage over sequential administration. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 28, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Pertuzumab – Treatment / Therapy for Breast Cancer
Roche / Genentech's Perjeta (Pertuzumab) is a humanised monoclonal antibody (MAb) to the HER2 receptor for the treatment of advanced breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - November 25, 2013 Category: Pharmaceuticals Source Type: news

EU Approves Trastuzumab Emtansine for HER2 Breast Cancer EU Approves Trastuzumab Emtansine for HER2 Breast Cancer
Kadcyla, the novel product that links trastuzumab with a cytotoxic, has been approved in the European Union (EU) for HER2 metastatic breast cancer. International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 20, 2013 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Roche's Kadcyla approved in the EU for advanced HER2-positive breast cancer
Roche today announced that Kadcyla (trastuzumab emtansine or T-DM1), the latest targeted medicine from its HER2 franchise and its first antibody-drug conjugate, has been approved by the European Commission for people with previously treated HER2-positive advanced breast cancer. (Source: Roche Media News)
Source: Roche Media News - November 20, 2013 Category: Pharmaceuticals Source Type: news

Featured in NEJM Journal Watch: Updated Guidelines for HER2 Testing in Breast Cancer (FREE)
By the NEJM Journal Watch Editors The guidelines carry recommendations for oncologists … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 8, 2013 Category: Primary Care Source Type: news

Kadcyla (Trastuzumab Emtansine) for Treatment of Breast Cancer
Kadcyla (trastuzumab emtansine) is an antibody drug conjugate indicated for the treatment of HER2-positive metastatic breast cancer (mBC). The drug has been developed by Genentech (a member of the Roche Group). (Source: Drug Development Technology)
Source: Drug Development Technology - October 21, 2013 Category: Pharmaceuticals Source Type: news

Updated Guidelines for HER2 Testing of Breast CancerUpdated Guidelines for HER2 Testing of Breast Cancer
Updated guidelines from the American Society of Clinical Oncology and the College of American Pathologists aim to improve the accuracy of testing. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 15, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Puma begins Phase II trial of cancer drug in solid tumour patients
US-based Puma Biotechnology has started Phase II clinical study of its lead drug candidate PB272 (neratinib) as a single agent for the treatment of patients with solid tumours and activating HER2 mutation (basket trial). (Source: Drug Development Technology)
Source: Drug Development Technology - October 8, 2013 Category: Pharmaceuticals Source Type: news

HER2 Testing Guide Clarifies Rules, Process (CME/CE)
(MedPage Today) -- Oncologists should determine HER2 status for every invasive breast cancer, including recurrent disease and adhere to specific histologic criteria to define results, according to an updated clinical guideline. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 8, 2013 Category: Hematology Source Type: news

Experts Urge Routine Test for All Patients With Invasive Breast Cancer
Standardized HER2 screen would help ensure women get appropriate therapy, guideline authors say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 7, 2013 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Nursing, Oncology, Pharmacy, Research, Preventive Medicine, News, Source Type: news

ECC: T-DM1 May Be New Standard of Care in Heavily Pretreated Advanced Breast Cancer
T-DM1, a combination drug of trastuzumab and a cell-killing drug emtansine, significantly improved progression-free survival in women with advanced HER2-positive breast cancer whose cancer has recurred or progressed despite previous treatments, according to the results of the TH3RESA trial. (Source: Cancer Network)
Source: Cancer Network - October 4, 2013 Category: Cancer & Oncology Source Type: news

Dose-Dense Anthracycline Safe With Anti-HER2 Drugs
Long-term safety and efficacy results of two phase II trials indicate that dose-dense anthracycline-based chemotherapy with doxorubicin and cyclophosphamide can be safely combined with anti-HER2 therapy in women with early breast cancer. (Source: Cancer Network)
Source: Cancer Network - October 3, 2013 Category: Cancer & Oncology Source Type: news

Merrimack enroll last patient in Phase II study of breast cancer drug
Merrimack Pharmaceuticals has enrolled the last patient in the second cohort of a two-cohort randomized Phase II clinical trial of MM-121 (SAR256212) in combination with paclitaxel in the neoadjuvant setting of HER2-negative breast cancer. (Source: Drug Development Technology)
Source: Drug Development Technology - October 2, 2013 Category: Pharmaceuticals Source Type: news

First pre-surgery breast cancer drug approved by FDA
The US Food and Drug Administration (FDA) has approved the first drug to be used in early stage breast cancer treatment. Perjeta (pertuzumab) will be used as part of a complete treatment regimen for patients before surgery (neoadjuvant setting). Perjeta was approved by the European Union in 2012 for the treatment of patients with advanced or late-stage (metastatic) HER2-positive breast cancer. HER2-positive breast cancers have increased amounts of the HER2 protein that contributes to cancer cell growth and survival... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 1, 2013 Category: Consumer Health News Tags: Regulatory Affairs / Drug Approvals Source Type: news

FDA Approves Pertuzumab for Neoadjuvant HER2-positive Breast Cancer
The U.S. Food and Drug Administration (FDA) today granted pertuzumab (Perjeta) accelerated approval for the treatment of patients with HER2-positive early stage breast cancer prior to surgery who are at high risk for recurrence or metastasis. (Source: Cancer Network)
Source: Cancer Network - October 1, 2013 Category: Cancer & Oncology Source Type: news